Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference23 articles.
1. Cohen AB. Point-counterpoint: cost-effectiveness analysis in medical care and the issue of economic model transparency. Med Care. 2017;55(11):907–8.
2. Cohen JT, Neumann PJ, Wong JB. A call for open-source cost-effectiveness analysis. Ann Intern Med. 2017;167(6):432–3.
3. Padula WV, McQueen RB, Pronovost PJ. Can economic model transparency improve provider interpretation of cost-effectiveness analysis? Evaluating tradeoffs presented by the second panel on cost-effectiveness in health and medicine. Med Care. 2017;55(11):909–11.
4. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7. Value Health. 2012;15(6):843–50.
5. Sullivan SD, Yeung K, Vogeler C, et al. Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm. 2015;21(4):269–75.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献